Biotech

All Articles

BMS ditches TIGIT, walking away from $200M bank on Agenus bispecific

.Bristol Myers Squibb is actually axing another huge bet coming from the Caforio era, ending an offe...

Nuvation stops wager inhibitor after taking into consideration stage 1 data

.After checking out at stage 1 data, Nuvation Bio has actually decided to stop work with its one-tim...

' Professional intuition' led FDA experts to back Zevra's unusual condition med

.Zevra Rehabs' rare disease medication appears to be on the course to confirmation this loss after o...

Pfizer takes $230M struck after axing neglected DMD genetics therapy

.Pfizer's stage 3 Duchenne muscle dystrophy (DMD) genetics treatment failure has actually gone a $23...

AC Immune sees 'site' possible in Alzheimer's drug records

.After greater than two decades of deal with neurodegenerative conditions, Swiss biotech AC Immune s...

GSK goes down ph. 2 HPV vaccine over shortage of best-in-class potential

.GSK has scrapped a phase 2 individual papillomavirus (HPV) vaccination from its own pipeline after ...

OS Treatments refiles $6M IPO to finance HER2 drug, preclinical ADCs

.OS Therapies are going to list on the NYSE American sell substitution today using a $6.4 thousand I...

ALX's waning CD47 action rate sends out sell spiraling down

.ALX Oncology's stage 2 gastric cancer reaction fee has actually compromised. After finding its CD47...

Ionis centers eye ailment from aim ats of Roche-partnered possibility after data dissatisfy

.An Additional of Ionis Pharmaceuticals' key midphase readouts has fallen short of desires, causing ...

Biogen's CEO claimed no high-risk deals in 2023. He's ready to become bold

.While Biogen's pharma peers are actually looking for late-stage possessions along with little bit o...